Biogen multiple sclerosis drug sales could fall $900M by 2020, analyst predicts – Boston Business Journal

Posted: Published on April 8th, 2017

This post was added by Dr Simmons


Investor's Business Daily
Biogen multiple sclerosis drug sales could fall $900M by 2020, analyst predicts
Boston Business Journal
Annual revenue from Biogen's multiple sclerosis treatments could decline $900 million by 2020 more than 10 percent amid increased competition from Roche's potential blockbuster Ocrevus and other drugs, according to an analyst. Leerink Partners ...
How Roche's 'Game Changer' Drug Will Chip Away At Biogen, NovartisInvestor's Business Daily

all 3 news articles »

Here is the original post:
Biogen multiple sclerosis drug sales could fall $900M by 2020, analyst predicts - Boston Business Journal

Related Posts
This entry was posted in MS Treatment. Bookmark the permalink.

Comments are closed.